Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.
Loading...
Embargo End Date
ICR Authors
Authors
Zangarini, M
Berry, P
Sludden, J
Raynaud, FI
Banerji, U
Jones, P
Edwards, D
Veal, GJ
Berry, P
Sludden, J
Raynaud, FI
Banerji, U
Jones, P
Edwards, D
Veal, GJ
Document Type
Journal Article
Date
2017-07-01
Date Accepted
2016-04-02
Abstract
AIM: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated. METHODS & RESULTS: Sample preparation involved protein precipitation with acetonitrile following addition of 13C15N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5-20,000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96-102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml. CONCLUSION: A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial.
Citation
Bioanalysis, 2017, 9 (13), pp. 1001 - 1010
Source Title
Publisher
FUTURE SCI LTD
ISSN
1757-6180
eISSN
1757-6199
Collections
Research Team
Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)